In contrast, data show less favorable outcomes with EGFR TKIs versus conventional platinum-based chemotherapy in patients with EGFR wild-type NSCLC and thus EGFR TKIs cannot be recommended in the first-line metastatic setting without evidence of a sensitizing EGFR mutation 16. This evidence concerns the gene EGFR and non-small cell lung carcinoma.